ProtoKinetix Discovers a Major New Market for AAGP(TM).VANCOUVER, British Columbia -- Within the medical, pharmaceutical and research industries, long term storage of cells and tissue is accomplished using cryopreservation cryopreservation /cryo·pres·er·va·tion/ (-prez?er-va´shun) maintenance of the viability of excised tissue or organs by storing at very low temperatures. cry·o·pres·er·va·tion n. . Cryopreservation is extreme cold storage at temperatures below -80[deg] C. At these low temperatures biologic activity, including biochemical reactions, are effectively stopped. Cells being preserved are often damaged during the freezing and the re-warming process. To minimize damage to cells and tissue being preserved, a solution containing Dimethyl di·meth·yl n. An organic compound, especially ethane, containing two methyl groups. Sulphoxide (DMSO DMSO dimethyl sulfoxide. DMSO n. Dimethyl sulfoxide; a colorless hygroscopic liquid obtained from lignin, used as a penetrant to convey medications into the tissues. DMSO, n. ) is often used. However, there remains a significant cell and tissue loss in standard cryopreservation. ITTEC Stem Inc. of Lavalle Quebec has just completed a series of experiments comparing cryopreservation techniques on human embryonic skin cells and Hela cells HeLa cells cells of the first continuously cultured carcinoma strain, descended from a human cervical carcinoma; used in the study of life processes, including viruses, at the cell level. . These cell lines were preserved following standard cryopreservation techniques using DMSO with and without AAGP AAGP American Association of Grant Professionals AAGP American Association of Geriatric Psychiatry AAGP American Academy of General Practice AAGP Aerobic Attached Growth Process AAGP Aeromedical Airlift Group AAGP Acoustic Analysis Guidance Product [TM]. When 8.6 mM of AAGP[TM]5 (di-amino acid AAGP[TM] molecule) was added to the solution, there was a 33.33% increase in cell survivability sur·viv·a·ble adj. 1. Capable of surviving: survivable organisms in a hostile environment. 2. That can be survived: a survivable, but very serious, illness. after 2 days of freezing at -80[deg] C. Details of these results are available on the ProtoKinetix (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :PKTX) website: www.protokinetix.com. AAGP[TM] has been shown to significantly improve the yield from cryopreservation and opens a very large market for Protokinetix Inc. The market in industry includes the preservation of cell lines, bacterial, yeast and fungal cultures. In human and veterinary medicine there is a large market for the preservation of semen, blood, stem cells, oocytes, embryos as well as tissue samples. In the biomedical research industry, the ability to utilize effective cryopreservation techniques is invaluable. About ProtoKinetix: ProtoKinetix Inc. is a Biotechnical Company dedicated to the development of a family of synthetic antifreeze antifreeze, substance added to a solvent to lower its freezing point. The solution formed is called an antifreeze mixture. Antifreeze is typically added to water in the cooling system of an internal-combustion engine so that it may be cooled below the freezing point glycoproteins (AAGP[TM]) for human and veterinary medicine, the bio technology and cosmetic industries, and as a food additive. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is conducting rapid and meaningful research with a view to developing markets for this very useful family of molecules. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission. On behalf of the Board of Directors Dr. John Todd - President |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion